Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer

Welcome to OncLive On Air^®! I’m your host today, Caroline Seymour.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with David R. Wise, MD, PhD. Dr Wise is an assistant professor in the Department of Medicine and Department of Urology at the NYU Grossman School of Medicine, part of NYU Langone Health.

In our exclusive interview, Dr Wise discussed practice-changing findings from the phase 3 ARASENS (NCT02799602) and PEACE1 (NCT01957436) trials. The ARASENS study investigated darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) and docetaxel in metastatic castration-sensitive prostate cancer. The triplet resulted in a 32.5% reduction in the risk of death compared with docetaxel and ADT alone. Additionally, at a 36-week follow-up, this trial demonstrated a 63% reduction in the risk of death in patients with undetectable prostate-specific antigen levels who received the darolutamide combination.

In the PEACE1 trial, the combination of ADT, docetaxel, abiraterone acetate (Zytiga), and radiotherapy showed a statistically significant improvement in overall survival (OS) and radiographic PFS (rPFS) in patients with metastatic hormone-naïve prostate cancer. The median rPFS in patients treated with the combination was 4.46 years vs 2.22 years in patients who did not receive abiraterone.

Dr. Wise highlighted how intensified treatment with doublet or triplet therapy can lead to better long-term outcomes in prostate cancer. He also outlined potential treatment sequencing options with the variety of available agents in this setting and discussed the importance of communication between patients and physicians so patients can receive optimal care tailored to their needs.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air^®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive^® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.

*OncLive On Air^® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.